Argentina loosens restrictions for biotech patents, says cabinet chief
Argentina's government has repealed a regulation that had restricted patents for biotech developments, cabinet chief Manuel Adorni announced. The move aligns the country with international standards and is expected to open new opportunities for biotech innovation and investment. The policy change signals a broader push to modernize Argentina's intellectual property framework in the life sciences sector.
The Atomic take
Argentina's old rules made it hard to patent biotech advances like engineered proteins and gene therapies, effectively pushing developers to file and commercialize elsewhere. Aligning with international standards gives longevity-focused startups and investors a reason to keep their work in-country, where Argentina already has strong basic science talent but a weak track record converting it into companies. Watch whether this draws actual venture funding and licensing deals into Argentine biotech, or whether enforcement and approval bottlenecks blunt the change.
Read the full story at Reuters →Know where humanity is headed.
Five forces. One brief. Free, every Monday morning.
Get The Atomic Five